Key points are not available for this paper at this time.
Abstract Background and Aims Emergence of multidrug resistance in non‐fermenting Gram‐negative bacilli is a threat to public health. Combination therapy is a strategy for the treatment of antibiotic‐resistant infections. Methods In this cross‐sectional study, a total of 63 nonduplicate clinical isolates of Acinetobacter baumannii and Pseudomonas aeruginosa were collected from various specimens. Identification of bacterial isolates was performed by phenotypic and molecular tests. Antibiotic susceptibility patterns and detection of β‐lactamase genes were determined using the broth microdilution and polymerase chain reaction (PCR) techniques, respectively. Then, the combined effects analysis was determined by the checkerboard method. Based on the status of resistance to carbapenems (imipenem and meropenem), 25 isolates of each genus were selected for further investigation. Results For A. baumannii, bla OXA‐23 , bla OXA‐58 , and bla OXA‐48 genes were positive in 21 (84%), 17 (68%), and 11 (44%) of isolates, respectively. In P. aeruginosa isolates, bla VIM was the most common gene (44%) and other genes including bla IMP , bla NDM , and bla OXA‐23 were found in nine (36%), six (24%), and three (12%) isolates, respectively. Meropenem (MER)‐tigecycline (TIG) had a significant synergistic effect against 20 (80%) A. baumannii ( p value < 0.001). This combination was also efficient against 5 (20%) P. aeruginosa isolates. Moreover, the other combination, tigecycline‐amikacin (TIG‐AMK) was effective against 10 (40%) A. baumannii isolates. The combination of colistin (COL) and MER showed a significant synergistic effect against 21 (84%) A. baumannii ( p value < 0.001) and 17 (68%) P. aeruginosa isolates ( p value < 0.001). Conclusion The MER‐TIG and COL‐MER combinations are promising options against resistant bacteria. Our study could be helpful for the development of a new treatment recommendation.
Kazemian et al. (Mon,) studied this question.